Physician profile
Nabil K Aboukhair
NPI 1508819509
$7,169.05
in general payments reported to CMS, 2019-2025
35 companies · $4,743 in 2025
The $4,743 reported for 2025 was more than what 93% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $291 · 2021: $825 · 2022: $376 · 2023: $435 · 2024: $165 · 2025: $4,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $761 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $760.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,668.16 | 2022-2025 | |
| Abbvie INC. | $834.35 | 2019-2025 | Lo Loestrin Fe, Ubrelvy |
| Exeltis, USA INC. | $145.34 | 2022-2024 | Nuvessa, Nuvessa |
| Mayne Pharma Commercial LLC | $138.06 | 2023-2025 | |
| Currax Pharmaceuticals LLC | $129.53 | 2019-2022 | |
| Braintree Laboratories, INC. | $118.47 | 2021-2024 | Sutab |
| Vivus LLC | $106.69 | 2019-2022 | |
| Lilly USA, LLC | $86.37 | 2019-2021 | |
| Therapeuticsmd, INC. | $79.45 | 2019-2021 | |
| Myovant Sciences INC. | $68.36 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $66.96 | 2021 | |
| Ethicon US, LLC | $59.78 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.41 | 2019-2022 | |
| Astellas Pharma US INC | $57.89 | 2023 | Veozah, Myrbetriq |
| Pfizer INC. | $51.27 | 2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $41.72 | 2023 | Myfembree |
| Mycovia Pharmaceuticals, INC. | $41.69 | 2022-2023 | Vivjoa |
| Hologic Sales and Service, LLC | $39.27 | 2019-2022 | |
| Allergan, INC. | $37.03 | 2019-2020 | |
| Millicent US INC | $33.41 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $32.48 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $29.69 | 2025 | Exparel |
| Merck Sharp & Dohme LLC | $28.82 | 2020 | |
| Mylan Pharmaceuticals INC. | $26.00 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $24.50 | 2019 | |
| Ibsa Pharma INC. | $21.64 | 2023 | Tirosint, Licart |
| Agile Therapeutics, INC. | $21.59 | 2021 | |
| Baxter Healthcare | $19.69 | 2021 | |
| Tersera Therapeutics LLC | $18.90 | 2022 | |
| Vertical Pharmaceuticals, LLC | $16.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.90 | 2021 | |
| Horizon Therapeutics Plc | $14.15 | 2019 | |
| Olympus America INC. | $12.75 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.53 | 2020 | |
| Evofem Biosciences, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Aboukhair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.